Promoting pan-European cancer research for the benefit of all cancer patients

Advances in understanding many of the fundamental mechanisms of cancer progression have led to the development of molecular targeted therapies. While molecular targeted therapeutics continue to improve the outcome for cancer patients, tumor heterogeneity among patients, as well as intratumoral heterogeneity, limits the efficacy of these drugs to specific patient subtypes, as well as contributes to relapse. Thus, there is a need for a more personalized approach toward drug development and diagnosis that takes into account the diversity of cancer patients, as well as the complex milieu of tumor cells within a single patient. Three-dimensional (3D) culture systems paired with patient-derived xenografts or patient-derived organoids may provide a more clinically relevant system to address issues presented by personalized or precision medical approaches. In this review, we cover the current methods available for applying 3D culture systems toward personalized cancer research and drug development, as well as key challenges that must be addressed in order to fully realize the potential of 3D patient-derived culture systems for cancer drug development. Greater implementation of 3D patient-derived culture systems in the cancer research field should accelerate the development of truly personalized medical therapies for cancer patients.

Download Full-text

Abstract P3-06-50: Thyroid function is associated with the response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial on behalf of the Dutch Breast Cancer Research Group (BOOG 2010-01)

10.1158/1538-7445.sabcs14-p3-06-50 ◽

2015 ◽

Author(s):

S de Groot ◽

A Charehbili ◽

L GM Janssen ◽

E M Dijkgraaf ◽

V THBM Smit ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Research ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Thyroid Function ◽

Research Group ◽

Breast Cancer Research ◽

Breast Cancer Patients ◽

Response To Neoadjuvant Chemotherapy

Download Full-text

Toward the World Code Against Cancer

Journal of Global Oncology ◽

10.1200/jgo.17.00145 ◽

2018 ◽

pp. 1-8 ◽

Cited By ~ 1

Author(s):

Carolina Espina ◽

Rolando Herrero ◽

Rengaswamy Sankaranarayanan ◽

Etienne Krug ◽

Christopher P. Wild ◽

...

Keyword(s):

Risk Factors ◽

Cancer Research ◽

Cancer Risk ◽

Regional Differences ◽

International Agency ◽

Evidence Based ◽

The World ◽

European Code ◽

Multiple Media ◽

European Cancer

Overwhelmed by an abundance of often confusing, ambiguous, or apparently contradictory messages on disease prevention in today’s multiple media streams, the general public would surely value authoritative, clear, and evidence-based instructions on how to actively contribute to the reduction of their cancer risk. The European Code Against Cancer is a set of 12 recommendations for individuals on how to reduce cancer risk. The Code carries the authority and reliability of expert scientists working under the coordination of the International Agency for Research on Cancer, the cancer research agency of the WHO. The Code’s messages are aimed at individuals and have been enthusiastically promoted by European cancer associations. The experience of developing and promoting the European Code has generated interest in developing analogous recommendations for other regions of the world. Under the overall umbrella of a World Code Against Cancer using the same International Agency for Research on Cancer methodology, regional Codes could be developed, focused on regions sufficiently large and distinct to merit development of versions adapted to regional differences in risk factors and cancer patterns. Consideration of such an adapted model illustrates why a simple translation of the European Code would not be sufficient to promote cancer prevention globally.

Download Full-text